Adalimumab
Measuring Adalimumab drug concentrations in patients being treated with Adalimumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Adalimumab allows for reliable measurement of Adalimumab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Adalimumab immediately before the next administration.
About Using Reagent
-
Sample Types
Whole blood, Serum, Plasma -
Reaction Time
10 mins -
Detection Range
0.2-50 μg/mL -
Intended Use
Quantitative determination of free adalimumab in human whole blood/serum/plasma
In Your Medical Field
AFIAS Adalimumab measures Adalimumab drug levels in patients' blood, using whole blood, serum, or plasma samples. This allows clinicians to obtain TDM results within just 10 minutes. It provides valuable insights into patients’ response to the treatment of Adalimumab.